Forest Labs Cuts Outlook

The company cites costs for marketing deals.
Author:
Publish date:

Forest Laboratories

(FRX)

said Wednesday that two recent marketing deals will force the company to reduce its earnings guidance for the fourth quarter and fiscal year each by 29 cents a share.

The company's fiscal year ends March 31. The New York-based drugmaker's announcement, which came after the markets had closed, means that Forest expects fourth-quarter earnings will be 22 cents a share and its fiscal-year profit will be $2.01. The fiscal-year guidance excludes a tax benefit of 10 cents a share that was recorded in the first quarter.

The marketing deals called for upfront payments to two companies during the quarter, raising Forest's R&D expenses to $405 million from $285 million. The payments are booked as R&D expenses because the drugs covered in these transactions are still experimental.

Forest paid

Mylan Laboratories

(MYL) - Get Report

$75 million as part of an agreement to develop and market a blood-pressure drug. Forest also has paid $50 million to

Replidyne

, a privately held Louisville, Colo., company, to develop and market an antibiotic for treating lung, sinus and skin infections.

Forest's stock gained 76 cents, or 1.6%, to close at $47.26.

As originally published, this story contained an error. Please see

Corrections and Clarifications.